Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.
| Website: | www.verastem.com |
| Email: | info@verastem.com |
| Main Phone: | +1 781 292-4200 |
| Address: | 117 Kendrick Street |
| Address 2: | Suite 500 |
| State: | MA |
| City / Town: | Needham |
| Country: | USA |
| Postal Code: | 02494 |
| Exchange: | NSD |
| CEO: | Brian M. Stuglik |
| Employees: | 169 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Umbralisib is in Phase 3 trials in hematologic malignancies.
For relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma (Image: Verastem)
Is this group ready to reverse course?
Reni Benjamin of Raymond James has watched biotechnology move into a new era in which cells and genes can be manipulated to produce true disease-modifying results. In this interview with The Life
It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the
At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative
Ken Griffin, billionaire hedge fund manager and founder of Citadel LLC, just put the brakes on E-Trade Financial Corp.'s (ETFC) 52-week high ($11.82 per share close Wednesday) with the
The Dow Jones Industrial Average rallied from a low of 12751.51 to a high of 12858, but the daily chart remains negative. The NASDAQ rallied from a low of 2920.54 to a high of 1940.28, but the
Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.
| Website: | www.verastem.com |
| Email: | info@verastem.com |
| Main Phone: | +1 781 292-4200 |
| Address: | 117 Kendrick Street |
| Address 2: | Suite 500 |
| State: | MA |
| City / Town: | Needham |
| Country: | USA |
| Postal Code: | 02494 |
| Exchange: | NSD |
| CEO: | Brian M. Stuglik |
| Employees: | 169 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Umbralisib is in Phase 3 trials in hematologic malignancies.
For relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma (Image: Verastem)
Is this group ready to reverse course?
Reni Benjamin of Raymond James has watched biotechnology move into a new era in which cells and genes can be manipulated to produce true disease-modifying results. In this interview with The Life
It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the
At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative
Ken Griffin, billionaire hedge fund manager and founder of Citadel LLC, just put the brakes on E-Trade Financial Corp.'s (ETFC) 52-week high ($11.82 per share close Wednesday) with the
The Dow Jones Industrial Average rallied from a low of 12751.51 to a high of 12858, but the daily chart remains negative. The NASDAQ rallied from a low of 2920.54 to a high of 1940.28, but the
| Last Price 1.41 | Change $ 0.035 | Change % 2.55 | Tick N/A |
| Bid 1.38 | Bid Size 100.00 | Ask 1.42 | Ask Size 1,800.00 |
| Open 1.42 | High 1.42 | Low 1.35 | Prev Close 1.37 |
| Last Trade | Volume 940,421 | 52 Wk Hi 4.58 | 52 Wk Low 0.83 |
| Market Cap 104.5 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 74,349,659.00 | EPS (TTM) -1.88 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 2 | 3 |
| Number of Buys | 2 | 3 |
| Number of Sells | 0 | 0 |
| Net Activity | 10700 | 71238 |
| Last 10 Buys | Shares |
|---|---|
| Steven H. Bloom | 1,000 |
| Joseph M. Lobacki | 1,000 |
| Timothy J. Barberich | 1,000 |
| Timothy J. Barberich | 1,000 |
| Monica Kleinman | 1,000 |
| John B. Green | 1,000 |
| Robert Forrester | 1,000 |
| John B. Green | 1,000 |
| Daniel Paterson | 1,000 |
| Robert Forrester | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| N/A | 0 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 17 | 17 | 17 | 17 |
| Low Target Price Estimate | 7 | 7 | 7 | 7 |
| Mean Target Price Estimate | 13.14 | 13.14 | 13.14 | 13.14 |
| Standard Deviation | 3.72 | 3.72 | 3.72 | 3.72 |
| Date of Most Recent Estimate | 05/31/18 | 05/22/18 | 05/22/18 | 05/31/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 424B5 | Prospectus filed under Rule 424(b)(5) | 39 | 2018-06-14 |
| S-3MEF | Registration of up to an additional 20% of securities for any offering registered on a S-3 | 7 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.14 | 1.14 | 1.17 | 1.17 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait